AI Terminal

MODULE: AI_ANALYST
Interactive Q&A, Risk Assessment, Summarization
MODULE: DATA_EXTRACT
Excel Export, XBRL Parsing, Table Digitization
MODULE: PEER_COMP
Sector Benchmarking, Sentiment Analysis
SYSTEM ACCESS LOCKED
Authenticate / Register Log In

Orion Oyj

Report Publication Announcement Jul 19, 2017

3232_fs_2017-07-19_5cd1ef47-f5eb-4572-b28e-55093568515b.html

Report Publication Announcement

Open in Viewer

Opens in native device viewer

Disclosure 353796

Orion - Financial Calendar

Orion Corporation's financial reporting and Annual General Meeting in 2018

ORION CORPORATION STOCK EXCHANGE RELEASE 19 JULY 2017 at 11.00 A.M. EEST Orion Corporation's financial reporting and Annual General Meeting in 2018 Orion Corporation will publish its Financial Statement Release 2017 on Wednesday, 7 February 2018. The publication dates of the Interim Reports and the Half-Year Financial Report in 2018 are as follows: Interim Report January-March 2018 Tuesday , 24 April 2018 Half-Year Financial Report January-June 2018 Wednesday, 18 July 2018 Interim Report January-September 2018 Wednesday, 24 October 2018 The Financial Statements and the report of the Board of Directors for 2017 will be published on the Company's website at the latest in week 9/2018. The Annual General Meeting is planned to be held on Tuesday, 20 March 2018 in Helsinki. Orion's financial reports and related presentation material are available on the Group's website at http://www.orion.fi/investors promptly after the publishing. The website also provides a possibility to register on Orion's mailing lists for releases. Orion Corporation Timo Lappalainen Olli Huotari President and CEO SVP, Corporate Functions Contact person: Lilli Riikonen, Communications Manager, tel. +358 10 426 2319 Publisher: Orion Corporation Communications Orionintie 1A, FI-02200 Espoo, Finland Homepage: www.orion.fi Orion is a globally operating Finnish pharmaceutical company - a builder of well-being. Orion develops, manufactures and markets human and veterinary pharmaceuticals, active pharmaceutical ingredients and diagnostic tests. The company is continuously developing new drugs and treatment methods. The core therapy areas of Orion's pharmaceutical R&D are central nervous system (CNS) disorders, oncology and respiratory for which Orion developes inhaled Easyhaler® pulmonary drugs. Orion's net sales in 2016 amounted to EUR 1,074 million and the company had about 3,500 employees. Orion's A and B shares are listed on Nasdaq Helsinki. Founded in 1917, Orion celebrates its centennial anniversary in 2017. []

Talk to a Data Expert

Have a question? We'll get back to you promptly.